The immune system ages on its own — and the fix that works is a better vaccine

The immune system grows old on a schedule of its own — a process called immunosenescence — and it is a large part of why an infection a young body shrugs off can kill an old one [s1]. The strongest evidence that this decline is real and at least partly correctable comes not from any supplement but from vaccines redesigned to force a protective response an aged immune system would not otherwise mount [s2][s3].

That framing matters, because "immune support" is one of the most heavily sold ideas in the longevity market, and almost none of it is tested against the thing it claims to fix.

What immunosenescence is

A 2017 review in Nature Immunology describes immunosenescence as a set of age-related changes across the immune system that together raise vulnerability to infectious disease [s1]. The changes hit the cells of the mostly adaptive immune system, the signalling molecules that maintain and direct it, and the lymphoid organs that coordinate both the upkeep of immune cells and the launching of a response [s1]. The most cited structural example is the thymus, the organ where T cells mature: it shrinks with age, and as it does the body's supply of fresh, naïve T cells falls and the repertoire available to recognise new threats narrows [s1]. The review also stresses that this is not a fixed clockwork decline — a person's lifetime of exposures, and even their resident microbes, shape how their immunity ages [s1].

Immune ageing is closely related to, but distinct from, inflammaging, the chronic low-grade inflammation that also rises with age; both are threads in the broader hallmarks-of-ageing account of how bodies grow old.

The proof is in what still works

The cleanest demonstration that immunosenescence is real — and can be partly outmuscled — is that older adults need more help from a vaccine to reach the same protection, and that engineering that help works.

Take influenza. A randomised, double-blind trial enrolled 31,989 adults aged 65 and older and compared a high-dose inactivated vaccine, carrying 60 micrograms of antigen per strain, against the standard 15-microgram dose [s2]. Laboratory-confirmed influenza occurred in 1.4% of the high-dose group versus 1.9% of the standard-dose group, a relative efficacy of 24.2% (95% confidence interval 9.7 to 36.5) [s2]. The very fact that older adults need four times the antigen to gain that edge is itself a measurement of an immune system that no longer responds as it did.

Shingles makes the point more dramatically. Reactivation of the chickenpox virus is a disease almost entirely of the ageing immune system, and an adjuvanted subunit vaccine was built to drive a response strong enough to overcome the deficit. In a phase 3 trial of 15,411 adults aged 50 and older, the vaccine's efficacy against shingles was 97.2% (95% CI 93.7 to 99.0), with just 6 cases in the vaccine group against 210 on placebo, and efficacy held between 96.6% and 97.9% across every age band [s3]. A well-designed adjuvant, in other words, can push an old immune system back to near-young performance for a specific target — the same protection that appears to carry the downstream signal against dementia seen in shingles-vaccine natural experiments. The cost is more reactogenicity: grade 3 symptoms were reported by 17.0% of vaccine recipients versus 3.2% on placebo [s3].

The gap the market skips

Here is the honest limit. Measuring immunosenescence, and even overriding it for one pathogen with a cleverer vaccine, is not the same as an intervention that rejuvenates immunity across the board. No supplement, "immune booster" or longevity protocol has been shown to reverse the underlying decline, and the two successes above are narrow by design — they defeat immunosenescence for a single virus, not for the ageing immune system as a whole [s2][s3]. This is the same trap that recurs across geroscience, where a marker can be moved, or a specific disease outrun, without the broader process of ageing shifting, a pattern also visible in cellular senescence research.

What to watch is whether anything can restore the source rather than compensate at the target — approaches aimed at regenerating thymic output or broadening the T-cell repertoire, tested for hard clinical outcomes rather than a blood marker. Until then, the accurate summary is that immune ageing is real and measurable, that the interventions proven to counter it are vaccines rather than pills, and that they buy protection one disease at a time.